動態

• 

  Mary Grace N. Tamio   shared news

  在 September 22 2023 at 02:35 PM 已編輯 public

  Noncoding RNA-Mediated High Expression of PFKFB3 Correlates with Poor Prognosis and Tumor Immune Infiltration of Lung Adenocarcinoma
  
  #tumorimmuneinfiltration #lungadenocarcinoma #journals #articles
  
  More info | ⬇️

  

  Noncoding RNA-Mediated High Expression of PFKFB3 Correlates with Poor Prognosis and Tumor Immune Infiltration of Lung Adenocarcinoma

  Demonstrated mRNA of PFKFB3 was upregulated in Lung Adenocarcinoma (LUAD) while its protein level was higher in LUAD than ...
  0 0 0 0 0 0 0

  comment 留言

  thumb_upLike

  share 分享
• 

  Mary Grace N. Tamio   shared news

  在 September 05 2023 at 07:22 PM 已編輯 public

  Bevacizumab-induced arrhythmia in a patient with lung adenocarcinoma: A case report
  
  #bevacizumab #arrhythmia #lungadenocarcinoma #journals #articles
  
  More info | ⬇️

  

  Bevacizumab-induced arrhythmia in a patient with lung adenocarcinoma: A case report

  Rationale: Cardiotoxicity is an important side effect of vascular endothelial growth factor inhib
  0 0 0 0 0 0 0

  comment 留言

  thumb_upLike

  share 分享
• 

  Mary Grace N. Tamio   shared news

  在 May 30 2023 at 10:03 PM 已編輯 public

  A case of metastatic lung adenocarcinoma of the bladder in a patient with no documented history of lung cancer
  
  #lungadenocarcinoma #lungcancer #journals #articles
  
  More info | ⬇️

  A case of metastatic lung adenocarcinoma of the bladder in a patient with no documented history of lung cancer

  Volume 49, July 2023, 102441Author links open overlay panel, , , AbstractMetastatic lesions of non-urological malignancies...
  0 0 0 0 0 0 0

  comment 留言

  thumb_upLike

  share 分享
• 

  Mary Grace N. Tamio   shared news

  在 November 03 2021 at 05:09 PM 已編輯 public

  Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma
  
  #carcinomatosis #osimertinib #lungadenocarcinoma #journals #articles
  
  For more information | ⬇️

  

  Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma

  Introduction:Approximately 25%–30% of patients with non-small cell lung cancer (NSCLC) develop central nervous system (CNS...
  0 0 0 0 0 0 0

  comment 留言

  thumb_upLike

  share 分享